Investigators successfully transplanted 13 kidneys into a group of 15 patients who were treated with intravenous immunoglobulin (IVIg) for HLA desensitization, according to a report of a pilot study in the September issue of the American Journal of Transplantation.
“Transplantation of patients possessing antibodies against allo-HLA antigens can be delayed for years,” write Denis Glotz, from the Hôpital Européen Georges Pompidou in Paris, France, and colleagues. “We have shown that administration of [IVIg] can induce a profound and sustained decrease in the titers of anti-HLA antibodies.”
Of 15 patients with antibodies against allo-HLA who were treated with IVIg, given as three monthly courses of 2 g/kg body weight, 13 patients (87%) were effectively desensitized and underwent immediate transplantation, 11 with a cadaveric donor, and two with a living donor against which the pretreatment cross-match was positive. One graft was lost from thrombosis and one from rejection. At follow-up of at least one year, all other patients remained free of rejection episodes or other complications.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!